Gabelli Funds LLC purchased a new stake in Ralliant Corporation (NYSE:RAL – Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 26,659 shares of the company’s stock, valued at approximately $1,166,000.
A number of other hedge funds have also recently bought and sold shares of RAL. Westfuller Advisors LLC acquired a new position in shares of Ralliant in the 3rd quarter valued at approximately $26,000. Manchester Capital Management LLC acquired a new stake in shares of Ralliant during the second quarter worth approximately $29,000. UMB Bank n.a. bought a new stake in shares of Ralliant in the third quarter worth $29,000. Webster Bank N. A. acquired a new stake in Ralliant in the third quarter valued at $31,000. Finally, Wilmington Savings Fund Society FSB acquired a new stake in Ralliant in the third quarter valued at $34,000.
Ralliant Stock Up 2.6%
Shares of NYSE:RAL opened at $45.79 on Thursday. The company’s fifty day moving average is $48.58 and its two-hundred day moving average is $46.72. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.58 and a current ratio of 0.84. Ralliant Corporation has a 1-year low of $37.27 and a 1-year high of $57.02. The stock has a market capitalization of $5.12 billion and a price-to-earnings ratio of 23.36.
Ralliant Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Monday, March 23rd. Shareholders of record on Monday, March 9th will be paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Monday, March 9th. Ralliant’s payout ratio is presently 10.20%.
Wall Street Analyst Weigh In
Several research analysts have weighed in on RAL shares. Morgan Stanley reissued an “overweight” rating and set a $45.00 price objective on shares of Ralliant in a report on Friday, February 6th. Weiss Ratings lowered shares of Ralliant from a “hold (c)” rating to a “sell (d)” rating in a research note on Thursday, February 5th. Zacks Research cut shares of Ralliant from a “hold” rating to a “strong sell” rating in a research report on Monday, February 9th. Oppenheimer decreased their price target on Ralliant from $60.00 to $50.00 and set an “outperform” rating for the company in a research note on Friday, February 6th. Finally, Royal Bank Of Canada lowered their price objective on Ralliant from $52.00 to $41.00 and set a “sector perform” rating for the company in a report on Friday, February 6th. Seven research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Ralliant presently has an average rating of “Hold” and an average price target of $50.50.
Insider Buying and Selling
In related news, Director Kate Mitchell purchased 2,350 shares of the business’s stock in a transaction that occurred on Tuesday, February 10th. The shares were acquired at an average price of $42.48 per share, with a total value of $99,828.00. Following the acquisition, the director owned 8,411 shares in the company, valued at approximately $357,299.28. This trade represents a 38.77% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Amir A. Kazmi acquired 2,545 shares of Ralliant stock in a transaction that occurred on Friday, February 6th. The shares were bought at an average price of $39.27 per share, with a total value of $99,942.15. Following the transaction, the senior vice president directly owned 39,699 shares in the company, valued at approximately $1,558,979.73. This trade represents a 6.85% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 8,145 shares of company stock valued at $332,233 over the last 90 days.
About Ralliant
Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.
The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.
Featured Articles
- Five stocks we like better than Ralliant
- “This AI Giant is About to Go Bust”
- I tried out Elon Musk’s new AI tech — it floored me
- “I just bought 10,000 shares of a $5 stock…”
- Elon Musk’s $1 Quadrillion AI IPO
- Is Trump Done? Shocking leak…
Want to see what other hedge funds are holding RAL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ralliant Corporation (NYSE:RAL – Free Report).
Receive News & Ratings for Ralliant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ralliant and related companies with MarketBeat.com's FREE daily email newsletter.
